Buprenorphine and Naloxone Treatment
Opioid dependence is considered a chronic relapsing condition, meaning that the treatment options are long-term and include a high level of patient support. Intravenous drug use often involves the sharing of syringes or needles. This can lead to the contraction of HIV, hepatitis B, hepatitis C and other illnesses. These risks are among the many reasons that treatment options should be explored as soon as possible. Pathway Healthcare practices MAT Plus™ which takes a multidisciplinary approach to treatment.
Our treatment usually begins with Suboxone, Zubsolv, or Bunavail, all of which contain a combination of buprenorphine and naloxone. Buprenorphine mimics other opioids like heroin, codeine, or morphine, but produces a less euphoric effect, which can make it easier to discontinue use. Meanwhile, the naloxone works to dissuade intravenous misuse and works to reduce the effects of opioids. This combination allows for a more convenient, sustainable approach (as compared to methadone) with less abuse potential, and reduced risk for overdose. In addition, on-going group therapy and monitoring is a critical part of the MAT Plus™ treatment practiced at Pathway Healthcare.
About Suboxone, Zubsolv, and Bunavail
Zubsolv is a tablet that is administered sublingually, much like Suboxone. Zubsolv is a prescription medicine used to treat adults who are addicted to opioid drugs (either prescription or illegal) as part of a complete treatment program that also includes counseling and behavioral therapy.
To learn more about Zubsolv, click here.